Symptom Burden in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy

Abstract

● Patients with ≥1 pharmacy claim for UMEC/VI OR FP/SAL 250mg during the 6 months closest to sample identification ● Age ≥65 as of calendar year 2017 ● Continuous Medicare Advantage enrolment during the 12-month baseline period ● ≥2 ICD-10-CM COPD diagnosis codes at least 30 days apart during the 12-month baseline period ● Patients with evidence of UMEC/VI AND/OR FP/SAL during 6 months prior to the study criteria period ● Patients with evidence of triple therapy during the 12-month baseline period ● Patients with ≥1 asthma ICD-10 diagnosis codes during the 12-month baseline period ● Diagnosis or treatment for lung cancer ● Missing or invalid demographic or insurance information